Business
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent Cushing's Syndrome to Initiate in the First Half of 2026 Multiple Clinical Trials Initiated for Early- and Late-Stage Candidates Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRN
About this update from Crinetics Pharmaceuticals, Inc.
[{"type":"image","alt":"Crinetics Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Crinetics Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/524edf87ef8b0571a758e030125d56ba"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aOuZTVe8JuMXu9hW1utV3A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/524edf87ef8b0571a758e030125d56ba","width":300,"height":102}},"lazy":false},{"type":"text","content":"PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December","length":138,"tagName":"p"},{"type":"text","content":"Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent Cushing's Syndrome to Initiate in the First Half of 2026","length":149,"tagName":"p"},{"type":"text","content":"Multiple Clinical Trials Initiated for Early- and Late-Stage Candidates","length":71,"tagName":"p"},{"type":"text","content":"Management Hosting Conference Call at 4:30 p.m. ET Today","length":56,"tagName":"p"},{"type":"text","content":"SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the fourth quarter and full year ended December 31, 2025.","length":354,"tagName":"p"},{"type":"text","content":"“2025 was a breakout year for Crinetics, as the approval and launch of Palsonify demonstrated our ability to bring an innovative therapy from concept to the patients who need it most,” said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. “With strong launch dynamics, we are now focused on building a business capable of scaling that success. We have the commercial infrastructure, the pipeline depth and the capital to build a premier, multi-product company that will define the future of endocrinology.”","length":531,"tagName":"p"},{"type":"text","content":"Full Year 2025 and Recent Highlights: ","length":37,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Secured FDA approval on September 25, 2025 for PALSONIFY a...